Members-only Site   |   Print Page   |   Contact Us   |   Sign In   |   Register
News & Press: Breaking News

Interview with Imprimis' Mark Baum

Monday, November 02, 2015   (0 Comments)
Posted by: Dagmar Anderson
Share |
State of Reform Exclusive: Mark Baum’s disruptive solution to the “drug pricing crisis” in the US

"When Turig Pharmaceuticals announced its decision to raise the price of Daraprim, a drug commonly used by HIV/AIDS patients to treat toxoplasmosis, to $750 a pill, Imprimis Pharmaceuticals (Nasdaq: IMMY) CEO Mark Baum stepped in with a response. The San Diego-based pharmaceutical compounding company announced that it would be offering a customizable compounded alternative to the drug at $1 a tablet. The announcement was greeted by an outpouring of support from patient advocacy groups and the media."

Click here to read the entire article.


Association Management Software Powered by YourMembership.com®  ::  Legal